GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Cash Flow from Investing

Prostatype Genomics AB (OSTO:PROGEN) Cash Flow from Investing : kr-0.07 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2023, Prostatype Genomics AB spent kr0.00 Mil on purchasing property, plant, equipment. It gained kr0.01 Mil from selling property, plant, and equipment. It spent kr0.00 Mil on purchasing business. It gained kr0.00 Mil from selling business. It spent kr0.00 Mil on purchasing investments. It gained kr0.00 Mil from selling investments. It paid kr0.00Mil for net Intangibles purchase and sale. And it paid kr0.00 Mil for other investing activities. In all, Prostatype Genomics AB gained kr0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2023.


Prostatype Genomics AB Cash Flow from Investing Historical Data

The historical data trend for Prostatype Genomics AB's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Cash Flow from Investing Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
Cash Flow from Investing
-4.66 -3.26 -2.50 - -8.57

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.07 0.01 -

Prostatype Genomics AB Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Prostatype Genomics AB's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Prostatype Genomics AB's Cash Flow from Investing for the quarter that ended in Jun. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Prostatype Genomics AB's purchase of property, plant, equipment for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB spent kr0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Prostatype Genomics AB's sale of property, plant, equipment for the three months ended in Jun. 2023 was kr0.01 Mil. It means Prostatype Genomics AB gained kr0.01 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Prostatype Genomics AB's purchase of business for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB spent kr0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Prostatype Genomics AB's sale of business for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB gained kr0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Prostatype Genomics AB's purchase of investment for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Prostatype Genomics AB's sale of investment for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB gained kr0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Prostatype Genomics AB's net Intangibles purchase and sale for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB paid kr0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Prostatype Genomics AB's cash from discontinued investing activities for the three months ended in Jun. 2023 was 0.00 Mil. It means Prostatype Genomics AB paid kr0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Prostatype Genomics AB's cash from other investing activities for the three months ended in Jun. 2023 was kr0.00 Mil. It means Prostatype Genomics AB paid kr0.00 Mil for other investing activities.


Prostatype Genomics AB Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines